Agency: Pathway
Product Description
ENTYVIO is a prescription biologic infusion drug, indicated for patients with moderate to severe ulcerative colitis (UC) and Crohn's Disease (CD).
Objective of the Campaign
Target Audience: Moderate to severe UC or CD patients whose treatments are failing, specifically 48% (Male) / 52% (Female) aged 25-54. Challenge: At launch, ENTYVIO had to overcome a huge share of voice deficit competing against Humira and Remicade, who owned most of the market share. Objectives: To drive awareness and education for ENTYVIO amongst uncontrolled UC and CD patients as a...